×
About 115 results

ALLMedicine™ Lambert-eaton Myasthenic Syndrome Center

Research & Reviews  36 results

Myasthenia gravis associated with a pelvic follicular lymphoma.
https://doi.org/10.1136/bcr-2021-248011
BMJ Case Reports; Willis C, Williamson M et. al.

Jan 15th, 2022 - An 81-year-old woman presented with neck weakness, dysarthria, dysphasia and left-sided ptosis. Myasthenia gravis (MG) was strongly suspected. Voltage gated calcium channel (VGCC) antibodies, associated with Lambert-Eaton myasthenic syndrome (LEMS...

Neuromuscular junction disorders beyond myasthenia gravis.
https://doi.org/10.1097/WCO.0000000000000972 10.3389/ineur.2019.00516
Current Opinion in Neurology; Oh SJ

Dec 17th, 2021 - To give an overview of the recent data on three autoimmune neuromuscular junction disorders with the recent Food Drug Administration (FDA) approval of amifampridine [3,4-Diaminopyridine (3,4-DAP) and 3,4-diaminopyridine phosphate (3,4-DAPP) for th...

3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464094
BMC Neurology; Zhang N, Hong D et. al.

Sep 27th, 2021 - Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of neuromuscular transmission. The objective was to examine the efficacy and safety of 3,4-diaminopyridine (3,4-DAP) in patients with LEMS. We searched several databases to ide...

Discordant SOX-1 antibodies results in paraneoplastic Lambert-Eaton syndrome diagnosis ...
https://doi.org/10.1016/j.clinbiochem.2021.08.004
Clinical Biochemistry; Pozo-Giraldez A, Rodríguez-Borja E et. al.

Aug 28th, 2021 - Anti-Sry-like high mobility group box 1 (anti SOX-1) proteins are rare onconeural antibodies associated with paraneoplastic Lambert-Eaton myasthenic syndrome (LEMS). Few patients with anti-SOX-1 antibodies and negative anti-glial nuclear antibody ...

Lambert-Eaton Myasthenic Syndrome and Dermatomyositis With Anti-TIF1-gamma Autoantibody...
https://doi.org/10.1097/CND.0000000000000318
Journal of Clinical Neuromuscular Disease; Isfort M, Mnatsakanova D et. al.

Feb 18th, 2021 - Lambert-Eaton myasthenic syndrome (LEMS) is a presynaptic neuromuscular junction disorder, and dermatomyositis (DM) is an idiopathic inflammatory myopathy. LEMS and DM are uncommon conditions that can present similarly and are often associated wit...

see more →

Guidelines  1 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

see more →

Drugs  2 results see all →

News  7 results

Ruzurgi approved for Lambert-Eaton myasthenic syndrome in patients under age 17
https://www.mdedge.com/clinicalneurologynews/article/200494/neuromuscular-disorders/ruzurgi-approved-lambert-eaton?channel=285
Mary Jo M. Dales, Clinical Neurology News

May 8th, 2019 - Amifampridine (Ruzurgi) has been approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune neuromuscular disorder, in patients aged 6 to less than 17 years, according to a statement from the Food and Drug Administra.

FDA OKs First Treatment for Kids With Lambert-Eaton Myasthenic Syndrome
https://www.medscape.com/viewarticle/912722

May 8th, 2019 - The US Food and Drug Administration (FDA) has approved the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Amifampridine (Ruzurgi, Jacobus Pharmacuetical) is an oral potassium channel blocker...

FDA OKs First Treatment for Kids With Lambert-Eaton Myasthenic Syndrome
https://www.staging.medscape.com/viewarticle/912722

May 8th, 2019 - The US Food and Drug Administration (FDA) has approved the first treatment for children with Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Amifampridine (Ruzurgi, Jacobus Pharmacuetical) is an oral potassium channel blocker...

A 56-Year-Old Woman With Paresthesia and Choking
https://reference.medscape.com/viewarticle/906864_3

Dec 26th, 2018 - Discussion Lambert-Eaton myasthenic syndrome (LEMS) is a rare disorder of the neuromuscular junction, which is the synapse between the motor nerve endings and their associated muscle receptors.[1] Antibodies against the voltage-gated calcium chann...

FDA OKs First Treatment for Lambert-Eaton Myasthenic Syndrome
https://www.staging.medscape.com/viewarticle/905808

Nov 30th, 2018 - The US Food and Drug Administration (FDA) has approved amifampridine (Firdapse, Catalyst Pharmaceuticals) 10-mg tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Amifampridine, a potassium channel blocker, is the fir...

see more →